H2020 funding for respiratory research: scaling up for the prevention and treatment of lung diseases

Vardavas, Constantine; Kyriakos, Christina N; Fernández, Esteve; Bamidis, Panagiotis D.; Siddiqi, Kamran; Chavannes, Niels H.; Kleij, Rianne van der; Parker, Gary; Radu-Loghin, Cornel; Ward, Brian; Berkouk, Karim

doi:10.1183/13993003.01417-2019

Cited by 7 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With dire prognoses, there are to date still no curative treatments to reduce the progression of the disease, suppress airway inflammation or restore functional parenchyma lost in emphysematous lungs [15,16]. In turn, significant efforts have focused on strategies of disease prevention given the enduring lack of therapeutic treatment options in COPD [12,17]. Parallel to this, the severity of bacterial respiratory tract infections (e.g.…”

Section: Introductionmentioning

confidence: 99%

Advanced human-relevant in vitro pulmonary platforms for respiratory therapeutics

Artzy‐Schnirman

Raviv

Flikshtain

et al. 2021

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Over the past years, advanced in vitro pulmonary platforms have witnessed exciting developments that are pushing beyond traditional preclinical cell culture methods. Here, we discuss ongoing efforts in bridging the gap between in vivo and in vitro interfaces and identify some of the bioengineering challenges that lie ahead in delivering new generations of human-relevant in vitro pulmonary platforms. Notably, in vitro strategies using foremost lung-on-chips and biocompatible "soft" membranes have focused on platforms that emphasize phenotypical endpoints recapitulating key physiological and cellular functions. We review some of the most recent in vitro studies underlining seminal therapeutic screens and translational applications and open our discussion to promising avenues of pulmonary therapeutic exploration focusing on liposomes. Undeniably, there still remains a recognized trade-off between the physiological and biological complexity of these novel in vitro lung models and their ability to deliver assays with throughput capabilities. The upcoming years are thus anticipated to see further developments in broadening the applicability of such in vitro systems and accelerating therapeutic exploration for drug discovery and translational medicine in treating respiratory disorders.

show abstract

Section: Introductionmentioning

confidence: 99%

Advanced human-relevant in vitro pulmonary platforms for respiratory therapeutics

Artzy‐Schnirman

Raviv

Flikshtain

et al. 2021

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

show abstract

“…71 The opportunity to help smokers, who mostly live in low-and middle-income countries, may lie within their public health systems. 72 Incorporating smoking cessation into the assistance programs of health centers facilitates the successful integration of approaches. 72 Undoubtedly, technologyenabled healthcare has a high potential to help improve outcomes in key-risk patients.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of a smoking cessation decision-making electronic tool (Pare de Fumar Conosco): A randomized clinical trial

Teixeira¹,

Galil

Cupertino

et al. 2022

Health Informatics J

View full text Add to dashboard Cite

There is an underutilization of smoking cessation treatment among patients with chronic conditions, which indicates a need for new strategies to engage them. Web-based smoking cessation decision-making tools can be beneficial. This study assessed the effectiveness of the Pare de Fumar Conosco software at increasing engagement to smoking cessation counseling groups among Brazilian smokers with chronic conditions. Clinical trial participants were randomized to Pare de Fumar Conosco or standard of care. Engagement in the smoking cessation counseling group was the primary outcome. Secondary outcomes included motivation level, cessation rate, completion, and treatment adherence. The t-tests and Chi-square analyzed baseline differences between groups and the Poisson models, the effects of the intervention. Engagement rates were higher in the Pare de Fumar Conosco (IR=2.22; 95% CI: 1.06 - 4.63) concerning the standard of care. Pare de Fumar Conosco group was more adherent to treatment over time (6.4% versus 4.2% in the final week). Cessation rate was 26.3% in standard care and 23.1% in Pare de Fumar Conosco. Both interventions maintained significant motivation levels to quit smoking. The Pare de Fumar Conosco intervention effectively increases the engagement in the smoking cessation counseling groups. There is a need to improve the smoking cessation rate.

show abstract

“…Research priorities identified by this systematic international process should inform and motivate policymakers, funders and researchers to support and conduct research to reduce the global burden of COPD. The largest gains should be expected in LMIC settings, as the large majority of COPD deaths occur in those settings [ 51 ]. The follow-up to this process should identify and map outcomes to currently funded research to highlight apparent gaps and opportunities for increased investment.…”

Section: Discussionmentioning

confidence: 99%

Research priorities to address the global burden of chronic obstructive pulmonary disease (COPD) in the next decade

et al. 2021

View full text Add to dashboard Cite

Background The global prevalence of chronic obstructive pulmonary disease (COPD) has increased markedly in recent decades. Given the scarcity of resources available to address global health challenges and respiratory medicine being relatively under-invested in, it is important to define research priorities for COPD globally. In this paper, we aim to identify a ranked set of COPD research priorities that need to be addressed in the next 10 years to substantially reduce the global impact of COPD. Methods We adapted the Child Health and Nutrition Research Initiative (CHNRI) methodology to identify global COPD research priorities. Results 62 experts contributed 230 research ideas, which were scored by 34 researchers according to six pre-defined criteria: answerability, effectiveness, feasibility, deliverability, burden reduction, and equity. The top-ranked research priority was the need for new effective strategies to support smoking cessation. Of the top 20 overall research priorities, six were focused on feasible and cost-effective pulmonary rehabilitation delivery and access, particularly in primary/community care and low-resource settings. Three of the top 10 overall priorities called for research on improved screening and accurate diagnostic methods for COPD in low-resource primary care settings. Further ideas that drew support involved a better understanding of risk factors for COPD, development of effective training programmes for health workers and physicians in low resource settings, and evaluation of novel interventions to encourage physical activity. Conclusions The experts agreed that the most pressing feasible research questions to address in the next decade for COPD reduction were on prevention, diagnosis and rehabilitation of COPD, especially in low resource settings. The largest gains should be expected in low- and middle-income countries (LMIC) settings, as the large majority of COPD deaths occur in those settings. Research priorities identified by this systematic international process should inform and motivate policymakers, funders, and researchers to support and conduct research to reduce the global burden of COPD.

show abstract

H2020 funding for respiratory research: scaling up for the prevention and treatment of lung diseases

Cited by 7 publications

References 22 publications

Advanced human-relevant in vitro pulmonary platforms for respiratory therapeutics

Advanced human-relevant in vitro pulmonary platforms for respiratory therapeutics

Effectiveness of a smoking cessation decision-making electronic tool (Pare de Fumar Conosco): A randomized clinical trial

Research priorities to address the global burden of chronic obstructive pulmonary disease (COPD) in the next decade

Contact Info

Product

Resources

About